Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections

World News: . []

Prof Achim Kaufhold Basileas Chief Medical Officer said With the agreement on the SPAs we are on track to initiate the pivotal phase 3 program under our contract with BARDA within the next three to six months We plan to initially seek US reg istrati...

More news and information about Basilea Pharmaceutica International AG

Published By:

Globe Newswire: 06:17 GMT Friday 21st April 2017

Published: .

Search for other references to "basilea" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers